Royalty Report: Drugs, Pain – Collection: 259207

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Pain

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 259207

License Grant
Licensee acquired intellectual property and related rights from Licensor to develop, formulate, make, sell, and sub-license lidocaine-based gel formulations (collectively, the Products) as commercially available drugs (e.g. a market approved drug via the U.S. Food and Drug Administration 505(b)(2) pathway), while any patent rights remain outstanding, as well as other conditions.
License Property
The Product is a lidocaine-based gel formulations sold as compounded drug formulations.

MAY-44 is a non-estrogen topical analgesic gel containing a patented pH-balanced formulation of 3.75% lidocaine and other essential excipients designed for use on mucosal surfaces. If FDA-approved, MAY-44 could become the first topical non-estrogen-based product indicated for this large underserved medical need. Anecdotal evidence has shown topical lidocaine, which only needs to be applied immediately prior to intercourse, can be highly effective (90%) for moderate to severe dyspareunia.

Field of Use
MAY-44 is a drug candidate for the treatment of dyspareunia, or pain experienced by women during sexual intercourse.

Dyspareunia is the term for recurring pain in the genital area or within the pelvis during sexual intercourse. The pain can be sharp or intense. It can occur before, during, or after sexual intercourse. Dyspareunia is more common in women than men.

IPSCIO Record ID: 258698

License Grant
The Company acquired intellectual property and related rights from Licensor to develop, formulate, make, sell, and sub-license lidocaine-based gel formulations (collectively, the Products).
License Property
The Product is a lidocaine-based gel formulations sold as compounded drug formulations.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 310525

License Grant
Licensor grants a sole and exclusive license, including the right to sublicense, to all of the Intellectual Property Rights including the rights to develop,  use, market, promote, and sell the Product in the Territory.

For the Option for additional Territories of Canada and Mexico, Licensor grants an option to extend this Agreement to cover a sole and exclusive, license, on royalty terms that are substantially similar to those set forth in this Agreement, with the right to sublicense, to the Intellectual Property Rights including the right to develop, use, market, promote, and sell Product in Canada and Mexico.

For the Trademark License Grant, Licensor grants an exclusive right and license, to use the Trademark in connection with the marketing, promotion, advertising, and sale or other distribution of the Product in the Territory.

For the Submission Package, Licensor grants an option for a sole and exclusive license, with the right to sublicense, to the Intellectual Property Rights including the right to develop, use, market, promote, and sell a topical formulation of lidocaine in a gel formulation (Development Product), whether sold over-the-counter or by prescription, for human use which falls within the claims of the Licensed Patents.

If Licensee exercises its option, the parties agree to license such Intellectual Property Rights on terms to be mutually agreed to by the parties.based substantially on the terms of this Agreement.

License Property
Licensor is the owner of certain patents, know-how and trademarks for the topical treatment of post-herpetic neuralgia, other forms of neuralgia and neuropathy and has the right to grant licenses to said patents, know-how, and trademarks.

The Patents are titled Method for Treating Nerve Injury Pain Associated with Shingles;  Method for Treating Nerve Injury Pain Associated with Shingles Herpes-Zoster and Post-Herpetic Neuralgia) by Topical Application Of Lidocaine;  Method for Treating Pain Associated with Herpes Zoster and Post-Herpetic Neuralgia;  and,  Method for Treating Nerve Injury Pain Associated with Shingles (Herpes-zoster and Post Herpetic Neuralgia) by Topical Application of Lidocaine.

Product means any topical formulation of lidocaine in a bandage and/or transdermal (Patch) formulation, whether sold over-the counter or by prescription, for human use which falls within the claims of the Licensed Patents.

Trademark shall mean the trademarks LIDODERM or TAKON that may be used to market the Product in the Territory.

Lidocaine patches are used to relieve the pain of post-herpetic neuralgia (PHN; the burning, stabbing pains, or aches that may last for months or years after a shingles infection). Lidocaine is in a class of medications called local anesthetics. It works by stopping nerves from sending pain signals.

Field of Use
This agreement is for the topical treatment of post-herpetic neuralgia, other forms of neuralgia and neuropathy in the United States.

Lidoderm(R) (Lidocaine Patch 5%) is a transdermal pharmaceutical patch product for the treatment of post-herpetic neuralgia.

Postherpetic neuralgia is the most common complication of shingles. The condition affects nerve fibers and skin, causing burning pain that lasts long after the rash and blisters of shingles disappear. The chickenpox (herpes zoster) virus causes shingles.

Licensee is a pharmaceutical company engaged in research, development, and marketing of various products, including pain management products.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.